Literature DB >> 28345412

Effect of Glucosamine Sulfate on Osteoarthritis in the Cruciate-Deficient Canine Model of Osteoarthritis.

Wolfram Wenz1, Christian Hornung2, Christopher Cramer3, Malte Schroeder3, Michael Hoffmann3.   

Abstract

Objective Osteoarthritis (OA) is a major cause of musculoskeletal pain and disability worldwide. The investigation of disease-modifying treatment options for OA has become an important aspect of orthopedic care. To assess the effect of intra-articular and oral glucosamine sulfate (GS) versus placebo on osteoarthritis in a canine model. Materials In this randomized, placebo-controlled, double-blinded study, OA was induced by anterior cruciate ligament transection (ACLT) according to the Pond-Nuki model in 32 canines. All canines were allocated into 4 treatment subgroups with treatment administered for 8 weeks: GS (400 mg) intra-articular, placebo intra-articular, GS (200 mg/kg body weight) oral, and placebo oral. The contralateral nonoperated stifle (knee) served as control. After 8 weeks, the medial and lateral femoral condyles, the medial and lateral tibial plateau and patella were histologically examined and anatomic changes quantified by light microscopy using the modified Mankin score. Results After 8 weeks, mean Mankin score values significantly ( P < 0.002) decreased in the intra-articular GS group (8.1; range 7.9-8.8) compared with the intra-articular placebo group (13.9; range 11.6-15.9) and again significantly ( P < 0.002) in the oral GS group (12.1; range 9.9-12.7) compared with the oral placebo group (15.1; range 12.5-17.0). Mean Mankin score values were significantly ( P < 0.002) lower in the intra-articular GS group compared with the oral GS group. Conclusion Both, intra-articular and oral administered GS significantly reduced histological signs of OA in the Pond-Nuki model, with the intra-articular application being more effective compared to oral administration.

Entities:  

Keywords:  articular cartilage; canine; drug therapy; experimental osteoarthritis; glucosamine sulfate; knee joint

Year:  2016        PMID: 28345412      PMCID: PMC5358821          DOI: 10.1177/1947603516638898

Source DB:  PubMed          Journal:  Cartilage        ISSN: 1947-6035            Impact factor:   4.634


  28 in total

1.  Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT.

Authors:  Allen D Sawitzke; Helen Shi; Martha F Finco; Dorothy D Dunlop; Crystal L Harris; Nora G Singer; John D Bradley; David Silver; Christopher G Jackson; Nancy E Lane; Chester V Oddis; Fred Wolfe; Jeffrey Lisse; Daniel E Furst; Clifton O Bingham; Domenic J Reda; Roland W Moskowitz; H James Williams; Daniel O Clegg
Journal:  Ann Rheum Dis       Date:  2010-06-04       Impact factor: 19.103

2.  Down regulation of interleukin 1beta production in human osteoarthritic synovial tissue and cartilage cultures by aminoguanidine.

Authors:  I Shirazi; I Yaron; Y Wollman; M Blum; T Chernihovsky; R Judovich; A Iaina; M Yaron
Journal:  Ann Rheum Dis       Date:  2001-04       Impact factor: 19.103

3.  Evaluation of the effect of glucosamine on an experimental rat osteoarthritis model.

Authors:  Kiyohito Naito; Taiji Watari; Atsushi Furuhata; Shin Yomogida; Koji Sakamoto; Hisashi Kurosawa; Kazuo Kaneko; Isao Nagaoka
Journal:  Life Sci       Date:  2010-02-24       Impact factor: 5.037

Review 4.  Current role of glucosamine in the treatment of osteoarthritis.

Authors:  J-Y Reginster; O Bruyere; A Neuprez
Journal:  Rheumatology (Oxford)       Date:  2007-03-31       Impact factor: 7.580

5.  Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study.

Authors:  Karel Pavelká; Jindriska Gatterová; Marta Olejarová; Stanislav Machacek; Giampaolo Giacovelli; Lucio C Rovati
Journal:  Arch Intern Med       Date:  2002-10-14

6.  Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial.

Authors:  J Y Reginster; R Deroisy; L C Rovati; R L Lee; E Lejeune; O Bruyere; G Giacovelli; Y Henrotin; J E Dacre; C Gossett
Journal:  Lancet       Date:  2001-01-27       Impact factor: 79.321

7.  Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Authors:  Daniel O Clegg; Domenic J Reda; Crystal L Harris; Marguerite A Klein; James R O'Dell; Michele M Hooper; John D Bradley; Clifton O Bingham; Michael H Weisman; Christopher G Jackson; Nancy E Lane; John J Cush; Larry W Moreland; H Ralph Schumacher; Chester V Oddis; Frederick Wolfe; Jerry A Molitor; David E Yocum; Thomas J Schnitzer; Daniel E Furst; Allen D Sawitzke; Helen Shi; Kenneth D Brandt; Roland W Moskowitz; H James Williams
Journal:  N Engl J Med       Date:  2006-02-23       Impact factor: 91.245

8.  Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine.

Authors:  J D Sandy; D Gamett; V Thompson; C Verscharen
Journal:  Biochem J       Date:  1998-10-01       Impact factor: 3.857

Review 9.  A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis.

Authors:  C Thomas Vangsness; William Spiker; Juliana Erickson
Journal:  Arthroscopy       Date:  2008-09-30       Impact factor: 4.772

10.  Differential metabolic effects of glucosamine and N-acetylglucosamine in human articular chondrocytes.

Authors:  A R Shikhman; D C Brinson; J Valbracht; M K Lotz
Journal:  Osteoarthritis Cartilage       Date:  2009-03-24       Impact factor: 6.576

View more
  2 in total

1.  A missense mutation in the catalytic domain of O-GlcNAc transferase links perturbations in protein O-GlcNAcylation to X-linked intellectual disability.

Authors:  Veronica M Pravata; Mehmet Gundogdu; Sergio G Bartual; Andrew T Ferenbach; Marios Stavridis; Katrin Õunap; Sander Pajusalu; Riina Žordania; Monica H Wojcik; Daan M F van Aalten
Journal:  FEBS Lett       Date:  2019-11-07       Impact factor: 3.864

2.  Dietary supplementation with glycosaminoglycans reduces locomotor problems in broiler chickens.

Authors:  Julyana M S Martins; Lindolfo D Dos Santos Neto; Raiana A Noleto-Mendonça; Genilson B de Carvalho; Sarah Sgavioli; Fabyola Barros de Carvalho; Nadja S M Leandro; Marcos B Café
Journal:  Poult Sci       Date:  2020-10-06       Impact factor: 3.352

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.